How Significant are Insulin Resistance Parameters in Subjects with Polycystic Ovarian Syndrome (PCOS)? A Cross-Sectional Study
DOI:
https://doi.org/10.51253/pafmj.v74i1.7958Keywords:
Cardiovascular Disease (CVD), Free Androgen Index (FAI), Homeostasis model assessment for insulin resistance (HOMA-IR), DihydrotestosteroneAbstract
Objective: To evaluate insulin resistance by “Homeostasis Model Assessment for Insulin Resistance (HOMA IR)” and related
cardiovascular disease risks in females with or without polycystic ovarian syndrome.
Study Design Comparative cross-sectional study.
Place and Duration of Study: Pakistan Navy Ship Hafeez Hospital, Islamabad Pakistan, from Jan 2018 to Dec 2019.
Methodology: Patients diagnosed to have polycystic ovarian syndrome (n=158) as per Rotterdam criteria were compared with non-PCOS patients (n=162) for HOMA IR and other CVD risks. Measurement of glucose, insulin, lipid parameters and HbA1c for all subjects was carried out in fasting. PCOS was diagnosed by “Rotterdam Criteria”. Free Androgen Index was measured as FAI=(Total testosterone/SHBG) x100. Differences in insulin resistance among polycystic ovarian syndrome and nonpolycystic ovarian syndrome females were measured by the non-parametric test.
Results: Our study included 158 females (49.38%) with PCOS defined as per Rotterdam criteria, while 162 subjects did not
have PCOS (50.62%). The differences between PCOS and non-PCOS were LH: 5.15±3.66 vs. 4.58±2.87 IU/L (p=0.121), FSH:
5.87±3.57 vs. 7.26±4.63 IU/L (0.003), total testosterone: 1.76±0.86 vs. 1.17±0.45 nmol/L (<0.001) and SHBG: 41.59±31.94 vs.
55.50±34.76 (p<0.001). Insulin resistance was higher in PCOS [(3.81±3.58, n=156) in comparison to non-PCOS (3.11±2.49,
n=162), p=0.091]. Both the presence of PCOS and obesity, as measured by BMI, were associated with higher HOMA-IR.
Conclusion: Insulin resistance was found to be higher in PCOS females than in non-PCOS females. BMI also contributed to
higher insulin resistance among our study population.
Downloads
Metrics
References
Kotake H, Oikawa S. Syndrome X. Nihon Rinsho 1999; 57(3):
–626.
Gluvic Z, Zaric B, Resanovic I, Resanovic I, Obradovic
M, Mitrovic A, et al. Link between Metabolic Syndrome and
Insulin Resistance. Curr Vasc Pharmacol 2017; 15(1): 30–39.
https://doi.org/10.2174/1570161114666161007164510.
Nolan CJ, Prentki M. Insulin resistance and insulin
hypersecretion in the metabolic syndrome and type 2 diabetes:
Time for a conceptual framework shift. Diab Vasc Dis Res 2019;
(2): 118–127. https://doi.org/10.1177/1479164119827611.
Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al.
Polycystic ovary syndrome. Nat Rev Dis Primers 2016; 2: 16057.
https://doi.org/10.1038/nrdp.2016.57.
Dewailly D. Diagnostic criteria for PCOS: Is there a need for a
rethink? Best Pract Res Clin Obstet Gynaecol 2016; 37: 5–11.
https://doi.org/10.1016/j.bpobgyn.2016.03.009.
Coutinho EA, Kauffman AS. The Role of the Brain in the
Pathogenesis and Physiology of Polycystic Ovary Syndrome
(PCOS). Med Sci (Basel) 2019; 7(8): 84.
https://doi.org/10.3390/medsci7080084.
Azziz R, Kintziger K, Li R, Laven J, Morin-Papunen L, Merkin
SS. Recommendations for epidemiologic and phenotypic
research in polycystic ovary syndrome: an androgen excess and
PCOS society resource. Hum Reprod 2019; 34(11): 2254–2265.
https://doi.org/10.1093/humrep/dez185.
Bannigida DM, Shivananda Nayak B, Vijayaraghavan R. Insulin
resistance and oxidative marker in women with PCOS. Arch
Physiol Biochem 2018: 1-4.
https://doi.org/10.1080/13813455.2018.1499120.
Elhassan YS, Idkowiak J, Smith K, Asia M, Helena Gleeson
H, Webster R, et al. Causes, Patterns, and Severity of Androgen
Excess in 1205 Consecutively Recruited Women. J Clin
Endocrinol Metab 2018; 103(3): 1214–1223.
https://doi.org/10.1210/jc.2017-02426.
Wang F, Zhang ZH, Xiao KZ, Wang ZC. Roles of HypothalamicPituitary-Adrenal Axis and Hypothalamus-Pituitary-Ovary Axis in the Abnormal Endocrine Functions in Patients with Polycystic
Ovary Syndrome. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2017;
(5): 699–704.https://doi.org/10.3881/j.issn.1000-503X.2017.05.017.
Mezzullo M, Fanelli F, Di Dalmazi G, Fazzini A, Ibarra-Gasparini
D, Mastroroberto M, et al. Salivary cortisol and cortisone
responses to short-term psychological stress challenge in late
adolescent and young women with different hyperandrogenic
states. Psychoneuroendocrinology 2018; 91: 31-40.
https://doi.org/10.1016/j.psyneuen.2018.02.022.
Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The
prevalence of polycystic ovary syndrome in reproductive-aged
women of different ethnicity: a systematic review and metaanalysis. Oncotarget 2017; 8(56): 96351–96358.
https://doi.org/10.18632/oncotarget.19180.
Kollmann M, Klaritsch P, Martins WP, Guenther F, Schneider V,
Herzog SA, et al. Maternal and neonatal outcomes in pregnant
women with PCOS: comparison of different diagnostic
definitions. Hum Reprod 2015; 30(10): 2396-403.
https://doi.org/10.1093/humrep/dev187.
Goodman NF, Bledsoe MB, Cobin RH, Futterweit W, Goldzieher
JW, Petak SM, et al; American Association of Clinical
Endocrinologists Hyperandrogenic Disorders Task Force.
American Association of Clinical Endocrinologists medical
guidelines for the clinical practice for the diagnosis and
treatment of hyperandrogenic disorders. Endocr Pract 2001; 7(2):
-134.
de Onis M, Habicht JP. Anthropometric reference data for
international use: recommendations from a World Health
Organization Expert Committee. Am J Clin Nutr 1996; 64(4): 650–
https://doi.org/10.1093/ajcn/64.4.650.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC. Homeostasis model assessment: insulin resistance
and beta-cell function from fasting plasma glucose and insulin
concentrations in man. Diabetologia 1985; 28: 412–419.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group. Revised 2003 consensus on diagnostic criteria
and long-term health risks related to polycystic ovary syndrome.
Fertil Steril 2004; 81(1): 19-25.
https://doi.org/10.1016/j.fertnstert.2003.10.004.
Bui HN, Sluss PM, Hayes FJ, Knol LD, Blankenstein
AM, Heijboer CA. Testosterone, free testosterone, and free
androgen index in women: Reference intervals, biological
variation, and diagnostic value in polycystic ovary syndrome.
Clin Chim Acta 2015; 450: 227–232.
https://doi.org/ 10.1016/j.cca.2015.08.019.
Belani M, Deo A, Shah P, Banker M, Singal P, Gupta S.
Differential insulin and steroidogenic signaling in insulin
resistant and non-insulin resistant human luteinized granulosa
cells-A study in PCOS patients. J Steroid Biochem Mol Biol 2018;
: 283-292. https://doi.org/ 10.1016/j.jsbmb.2018.01.008.
Aye MM, Butler AE, Kilpatrick ES, Kirk R, Vince R, Rigby AS, et
al. Dynamic Change in Insulin Resistance Induced by Free Fatty
Acids Is Unchanged Though Insulin Sensitivity Improves
Following Endurance Exercise in PCOS. Front Endocrinol
(Lausanne) 2018; 9: 592.
https://doi.org/ 10.3389/fendo.2018.00592.
Coutinho EA, Kauffman AS. The Role of the Brain in the
Pathogenesis and Physiology of Polycystic Ovary Syndrome
(PCOS). Med Sci (Basel) 2019; 7(8): 84.
https://doi.org/ 10.3390/medsci7080084.
Esparza LA, Schafer D, Ho BS, Thackray VG, Kauffman AS.
Hyperactive LH Pulses and Elevated Kisspeptin and NKB Gene
Expression in the Arcuate Nucleus of a PCOS Mouse Model.
Endocrinology 2020; 161(4): bqaa018.
https://doi.org/ 10.1210/endocr/bqaa018.
Engmann L, Jin S, Sun F, Legro RS, Polotsky AJ, Hansen KR, et
al. Racial and ethnic differences in the polycystic ovary
syndrome metabolic phenotype. Am J Obstet Gynecol 2017;
(5): 493.e1-493.e13. https://doi.org/10.1016/j.ajog.2017.01.003
Downloads
Published
How to Cite
Issue
Section
